📊 SNGX Key Takeaways
Is Soligenix, Inc.. (SNGX) a Good Investment?
Soligenix is in severe financial distress with revenue collapsed 85.8% YoY to just $119K while burning $10.3M annually in operating cash. With only $7.9M in cash reserves, the company faces less than one year of runway at current burn rates.
Why Buy Soligenix, Inc.. Stock? SNGX Key Strengths
- Gross margin of 81.5% demonstrates strong unit economics when products achieve sales
- No long-term debt provides financial flexibility and eliminates leverage risk
- Current liquidity of 2.39x ratio provides short-term operational sustainability
SNGX Stock Risks: Soligenix, Inc.. Investment Risks
- Revenue collapsed 85.8% YoY to just $119.4K indicating fundamental product or commercialization failure
- Operating cash burn of $10.3M annually against only $7.9M cash reserves threatens survival within one year
- Pharmaceutical company losing revenue suggests failed pipeline, discontinued products, or failed market execution
Key Metrics to Watch
- Cash balance depletion rate and burn trajectory
- Revenue stabilization, recovery, or announcement of new product commercialization
- Operating cash flow improvement and path to profitability
Soligenix, Inc.. (SNGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.39x current ratio provides a solid financial cushion.
SNGX Profit Margin, ROE & Profitability Analysis
SNGX vs Healthcare Sector: How Soligenix, Inc.. Compares
How Soligenix, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Soligenix, Inc.. Stock Overvalued? SNGX Valuation Analysis 2026
Based on fundamental analysis, Soligenix, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Soligenix, Inc.. Balance Sheet: SNGX Debt, Cash & Liquidity
SNGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Soligenix, Inc..'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-4.98 indicates the company is currently unprofitable.
SNGX Revenue Growth, EPS Growth & YoY Performance
SNGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $119.4K | -$1.7M | $-0.58 |
| Q2 2025 | $2.3K | -$1.6M | $-0.82 |
| Q1 2025 | $117.0K | -$1.9M | $-1.06 |
| Q3 2024 | $119.4K | -$1.7M | $-0.78 |
| Q2 2024 | $2.3K | -$1.6M | $-1.31 |
| Q1 2024 | $117.0K | -$1.0M | $-0.18 |
| Q3 2023 | $130.4K | -$1.7M | $-0.16 |
| Q2 2023 | $206.9K | -$1.6M | $-0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Soligenix, Inc.. Dividends, Buybacks & Capital Allocation
SNGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Soligenix, Inc.. (CIK: 0000812796)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SNGX
What is the AI rating for SNGX?
Soligenix, Inc.. (SNGX) has an AI rating of STRONG SELL with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNGX's key strengths?
Claude: Gross margin of 81.5% demonstrates strong unit economics when products achieve sales. No long-term debt provides financial flexibility and eliminates leverage risk.
What are the risks of investing in SNGX?
Claude: Revenue collapsed 85.8% YoY to just $119.4K indicating fundamental product or commercialization failure. Operating cash burn of $10.3M annually against only $7.9M cash reserves threatens survival within one year.
What is SNGX's revenue and growth?
Soligenix, Inc.. reported revenue of $119.4K.
Does SNGX pay dividends?
Soligenix, Inc.. does not currently pay dividends.
Where can I find SNGX SEC filings?
Official SEC filings for Soligenix, Inc.. (CIK: 0000812796) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNGX's EPS?
Soligenix, Inc.. has a diluted EPS of $-2.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SNGX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Soligenix, Inc.. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SNGX stock overvalued or undervalued?
Valuation metrics for SNGX: ROE of -209.4% (sector avg: 15%), net margin of -9,282.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SNGX stock in 2026?
Our dual AI analysis gives Soligenix, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SNGX's free cash flow?
Soligenix, Inc..'s operating cash flow is $-10.3M, with capital expenditures of $5.9K. FCF margin is -8,605.5%.
How does SNGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,282.3% (avg: 12%), ROE -209.4% (avg: 15%), current ratio 2.39 (avg: 2).